T-Cell Receptor Engineered T-Cell Therapy: A Rapidly Evolving Treatment Paradigm for Solid Tumors

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• Peripheral blood lymphocytes can be modified to express T-cell receptors (TCRs).
• These engineered TCRs recognize human leukocyte antigen (HLA)-restricted cancer antigens.
• Systemic administration of these engineered cells constitutes TCR-T cell therapy.

Purpose of the Study:

• To highlight the expanding potential of TCR-T cell therapy for solid tumors.
• To discuss the growing list of targetable tumor-exclusive antigens.
• To position TCR-T cell therapy as a promising investigational treatment for specific epithelial cancers.

Main Methods:

• Engineering peripheral blood lymphocytes to express specific TCRs.
• Identifying and characterizing tumor-exclusive antigens (e.g., cancer germline antigens, viral oncoproteins, neoantigens).
• Clinical evaluation of TCR-T cell therapy in patients with various solid tumors.

Main Results:

• TCR-T cell therapy has demonstrated clinical efficacy in metastatic melanoma and certain sarcomas.
• A diverse range of tumor-exclusive antigens are being identified for targeted therapy.
• The therapy is emerging as a promising option for mismatch repair proficient epithelial cancers.

Conclusions:

• TCR-T cell therapy is a rapidly advancing field with broad potential in oncology.
• The identification of novel cancer antigens is crucial for expanding treatment applications.
• This therapy represents a significant development in the fight against solid tumors, particularly epithelial cancers.